论文部分内容阅读
目的观察拉米夫定联合氧化苦参碱治疗慢性病毒性乙型肝炎的疗效。方法入选慢性乙型病毒性肝炎90例,随机分为拉米夫定加氧化苦参碱联合治疗组,单用拉米夫定组和单用氧化苦参碱组,拉米夫定和氧化苦参碱的疗程均为1年。结果联合治疗组到治疗12个月,HBV DNA阴转率高达86.67%,与单用拉米夫定组63.3%相比,有显著性差异(P<0.05),与单用氧化苦参碱组30.00%相比较,P<0.001,亦有显著性差异。联合治疗组疗程12个月时,HBeAg/Anti-HBe血清转换率达66.67%,而对照单用拉米夫定组为43.33%,单用氧化苦参碱组仅为26.67%,经统计学分析均P<0.05,有显著性差异。联合抗病毒治疗,YMDD的变异率明显较单用拉米夫定治疗组低(P<0.05),而单用氧化苦参碱组治疗期间没用发现YMDD变异。结论拉米夫定联合氧化苦参碱治疗慢性乙型病毒性肝炎的疗效显著优于单用拉米夫定或单用氧化苦参碱组,而且联合抗病毒组YMDD的变异率明显较单用拉米夫定治疗组低,值得推广应用。
Objective To observe the efficacy of lamivudine combined with oxymatrine in the treatment of chronic viral hepatitis. Methods 90 cases of chronic hepatitis B were randomly divided into lamivudine plus oxymatrine combined treatment group, lamivudine alone group and oxymatrine alone group, lamivudine and oxytocin Alkali treatment are 1 year. Results After 12 months of treatment, the negative rate of HBV DNA was 86.67% in the combined treatment group, which was significantly lower than that in the monotherapy lamivudine group (63.3%, P <0.05) 30.00%, P <0.001, there are also significant differences. HBeAg / Anti-HBe seroconversion rate was 66.67% in the combination therapy group at 12 months, compared with 43.33% in the control group and only 26.67% in the oxymatrine group alone. The statistical analysis All P <0.05, there are significant differences. In combination with antiviral therapy, the mutation rate of YMDD was significantly lower than that of lamivudine alone (P <0.05), while YMDD mutation was not found during the treatment with oxymatrine alone. Conclusion The efficacy of lamivudine combined with oxymatrine in the treatment of chronic hepatitis B is significantly better than that of lamivudine alone or oxymatrine alone, and the mutation rate of YMDD in combined antiviral group is significantly higher than that of monotherapy Lamivudine treatment group is low, it is worth promoting application.